1 2	Cyanobacterial peptides beyond microcystins – A review on co-occurrence, toxicity, and challenges for risk assessment
3 4	Elisabeth ML. Janssen
5	
6	Swiss Federal Institute of Aquatic Science and Technology, Eawag, Dübendorf, 8600,
7	Switzerland
8	E-mail: elisabeth.janssen@eawag.ch
9	Phone: + 41 58 765 5802
10	
11	
12	
13	Abstract
14	1. Introduction
15	2. Cyanopeptides beyond microcystins
16	3. Occurrence of cyanopeptides during bloom events
17	4. Toxicity of cyanopeptides
18	5. Implications for risk assessment
19	6. Conclusions 27
20	Acknowledgments
21	References
22	
23	

This document is the accepted manuscript version of the following article: Janssen, E. M. L. (2019). Cyanobacterial peptides beyond microcystins – A review on co-occurrence, toxicity, and challenges for risk assessment. Water Research. https://doi.org/10.1016/j.watres.2018.12.048

This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/

Abstract

Cyanobacterial bloom events that produce natural toxins occur in freshwaters across the
globe, yet the potential risk of many cyanobacterial metabolites remains mostly unknown.
Only microcystins, one class of cyanopeptides, have been studied intensively and the wealth
of evidence regarding exposure concentrations and toxicity led to their inclusion in risk
management frameworks for water quality. However, cyanobacteria produce an incredible
diversity of hundreds of cyanopeptides beyond the class of microcystins. The question arises,
whether the other cyanopeptides are in fact of no human and ecological concern or whether
these compounds merely received (too) little attention thus far. Current observations suggest
that an assessment of their (eco)toxicological risk is indeed relevant: First, other
cyanopeptides, including cyanopeptolins and anabaenopeptins, can occur just as frequently
and at similar nanomolar concentrations as microcystins in surface waters. Second,
cyanopeptolins, anabaenopeptins, aeruginosins and microginins inhibit proteases in the
nanomolar range, in contrast to protein phosphatase inhibition by microcystins.
Cyanopeptolins, aeruginosins, and aerucyclamide also show toxicity against grazers in the
micromolar range comparable to microcystins. The key challenge for a comprehensive risk
assessment of cyanopeptides remains their large structural diversity, lack of reference
standards, and high analytical requirements for identification and quantification. One way
forward would be a prevalence study to identify the priority candidates of tentatively
abundant, persistent, and toxic cyanopeptides to make comprehensive risk assessments more
manageable.

Keywords: Harmful algal bloom, cyanobacteria, toxin, risk assessment, ecotoxicology, human health

1. Introduction

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Our ecosystems and drinking water resources are not only vulnerable towards anthropogenic pollutants but also natural toxins (Bucheli 2014). Among the natural toxins from organisms of various kingdoms, those produced by aquatic organisms, such as cyanobacteria (blue green "algae"), are of particular concern for water resources since these waterborne toxins are released directly into surface waters when the cells die (Bogialli et al. 2017, Flores and Caixach 2015, Saker et al. 2005). Because cyanobacteria produce a diverse mixture of potentially toxic metabolites, there is a need to identify which of these metabolites are of toxicological concern. Cyanobacteria can grow to extremely high densities forming so-called harmful (algal) blooms within few days or weeks. Such blooms generally occur at warmer temperatures, higher nutrient loads, adequate light penetration into the water and residence time of the water (Schindler 2006, Whitton 2012). Cyanobacterial bloom events have deleterious effects on the ecosystem and on human activities, including decreased biodiversity, higher oxygen consumption due to decaying biomass, restriction of recreational activities, limited usability of water for agriculture, and additional technical measures to provide safe drinking water. While bloom events occur also under pristine conditions and at colder temperatures (Ostermaier and Kurmayer 2010, Trout-Haney et al. 2016), anthropogenic pressure contributes to extended warm periods, and high nutrient loads that favor growth of cyanobacteria (O'Neil et al. 2012). Cyanobacterial blooms occur regularly in numerous lakes (Baumann and Juttner 2008, Gkelis et al. 2015, Kurmayer et al. 2011, Lopes et al. 2012, Mazur-Marzec et al. 2013) and drinking water reservoirs (Ferranti et al. 2013, Grabowska et al. 2014, Jancula et al. 2014, Welker et al. 2006) but our knowledge about the potential risks of the secondary metabolites produced by cyanobacteria remains limited.

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

Among the bioactive metabolites, cyanobacteria produce low molecular weight toxins, including anatoxin, saxitoxin, and cylindrospermopsin but also non-ribosomal oligopeptides, termed cyanopeptides, which this review will focus on. To date, microcystins are the one class of cyanopeptides that is studied most intensely across scientific disciplines, with more than 300 journal articles published annually on the topic (Figure 1A). The dominance of studies on microcystins may have been catalyzed by the early link of this compound class to human intoxications. In 1996, the death of 52 dialysis patients due to liver failure was traced back to water contaminated with cyanobacteria and the presence of microcystins in a Brazilian hospital (Carmichael et al. 2001, Pouria et al. 1998). These tragic incidents in Brazil triggered the interest in assessing toxicity of microcystins and monitoring environmental concentrations. In addition, intoxication of human has been reported across the globe mostly by recreational exposure through inhalation of aerosols or swallowing contaminated surface water and a comprehensive review on epidemiological research can be found elsewhere (Svircev et al. 2017). Essentially for every country on the globe at least one ISI publication documents the occurrence of microcystin-producing cyanobacteria (Meriluoto et al. 2017, Trout-Haney et al. 2016). Because microcystins are potent liver toxins and can occur at up to micromolar concentrations during cyanobacterial bloom events, several countries include microcystins in their risk management frameworks for water quality (Ibelings et al. 2014). Despite the wealth of publications, even microcystins remain an active field of research, for example to better understand why cyanobacteria produce these complex molecules, how production is regulated, how water treatment can be improved for their effective removal, and which regulatory implementations are needed to protect human and ecosystem health during bloom events (Ibelings et al. 2014). While microcystins are of ecotoxicological concern, several studies with cyanobacterial

extracts observed toxic effects that could not be explained by the presence of microcystins

alone, suggesting that other bioactive metabolites need to be considered in risk assessment as well (Baumann and Juttner 2008, Keil et al. 2002, Le Manach et al. 2016, Smutna et al. 2014, Teneva et al. 2003, Teneva et al. 2005). Recent advancements of analytical techniques enabled researcher to identify hundreds of cyanopeptides beyond the well-known class of microcystins including cyanopeptolins, anabaenopeptins, aerucyclamides, aeruginosines, and microginins with a multitude of structural variants within each class (Welker and von Döhren 2006). However, these cyanopeptides have received little attention thus far regarding their potential human and ecological risk.

This article raises awareness for the diversity of biologically active and potentially toxic cyanopeptides that human and wildlife can be exposed to during cyanobacterial bloom events. Information regarding co-occurrence of cyanopeptides, potential exposure

concentrations in surface waters, and toxic effects is synthesized with a particular focus on

quantitative data rather than phenomenological observations. Key challenges and research

2. Cyanopeptides beyond microcystins

needs towards a risk assessment of cyanopeptide are discussed.

The 1990s present the onset of ever-increasing records of cyanopeptide studies not only for microcystins but also for nodularin, aeruginosins, anabaenopeptins, cyanopeptolins, microginins, microviridins, and aerucyclamides in the 2000s, among others (Figure 1). Over the past decades a legion of other cyanopeptides beyond microcystins has been identified in pure cultures and biomass collected from cyanobacterial bloom events (Beversdorf et al. 2017, Bogialli et al. 2017, Flores and Caixach 2015, Saker et al. 2005, Welker et al. 2004). In the 1960s, some early studies reported the production of aeruginosins from *Microcystis aeruginosa*, a cyanobacterial genus renowned for producing also microcystins (Herbert and Holliman 1964, Holliman 1969, Murakami et al. 1995, Namikoshi and Rinehart 1996).

Despite the increasing scientific output across cyanopeptide classes, the publication records are heavily disproportionate as studies on cyanopeptides other than microcystins represent less than 10% of the total scientific output. Particularly, few studies are available within the disciplines of environmental chemistry with less than 100 studies for *other* cyanopeptides together compared to more than 2,000 studies focusing on environmental behavior of microcystins alone. Here, the key challenge for a systematic risk assessment is the large diversity of cyanopeptides. This article will first demonstrate the structural diversity of cyanopeptides before presenting the current understanding of their co-occurrence, exposure concentrations, and quantitative information about toxicity.




Figure 1. Cumulative number of publications of scientific articles excluding review articles (retrieval from SciFinder 20 June 2018) for the topic of (A) microcystin, nodularin, and harmful algal bloom with annual

publication numbers shown in the insert and for the topics and (B) seven other classes of cyanopeptides in order of the number of publication records. Data is non-exclusive, meaning that one reference may be assigned to multiple categories.

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

134

135

136

2.1. Structural diversity

Peptides comprise more than 60 percent of the known biological active compounds produced by cyanobacteria (Chlipala et al. 2011). In addition to more than 240 microcystins, a minimum of 500 cyanopeptides ranging from 400-1900 Da have been structurally identified to date and with their variety comes the complexity of the naming system (Meriluoto et al. 2017, Welker and von Döhren 2006). Cyanopeptides consist of cyclic and linear nonribosomal peptides that can also contain non-proteinogenic residues and posttranslational modifications. Welker and Döhren presented a classification of cyanopeptides based on conserved molecular substructures (Welker and von Döhren 2006). Each class contains a characteristic substructure with a shared biosynthesis pathway while variations of monomers define the different variants within each class. For example, microcystins are heptapeptides with the characteristic Adda moiety (3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl-deca-4,6-dienoic acid) and the different variants result from altering monomers in mainly two positions. The variation is typically expressed by adding the one letter code of the amino acid, so that microcystin-LR refers to the variant with leucine (L) and arginine (R) in positions (2) and (4), respectively. However, the one letter code is limited to the standard amino acids and other modifications require more elaborate suffixes. Nodularins are hexapeptides with a similar structure to microcystins including the Adda moiety. Structural representations of prominent classes beyond microcystins are presented in Figure 2 including the cyclic classes of cyanopeptolins, anabaenopeptins, and (aeru)cyclamides as well as linear peptides classes of aeruginosines and microginins. Each class contains a conserved substructure indicative of this class and variable building blocks. Other than microcystins,

more than two monomeric building blocks can vary in these peptides, resulting in a large
combinatorial set of isoforms within each cyanopeptide class. For example, anabaenopeptins
carry characteristic ureido bond and several variations in the other five building block is
possible (details in Box 1). Among the cyanopeptides beyond microcystins, cyanopeptolins
contain the most structurally known compounds (approx. 36%), followed by microginins
(approx. 14%), aeruginosins (13%), cryptophycins and anabaenopeptins (approx. 9% each).
Other than these cyanopeptide classes, the depsopeptidic crytophycins have mostly been
isolated from <i>Nostoc sp.</i> and not from a variety of other cyanobacteria (Schwartz et al. 1990).
Often several synonyms exist for the same class of cyanopeptides or individual compounds
because no standardized naming systems existed early on. For example, the class of
cyanopeptolins is also referred to as microcystilides, micropeptins, aeruginopeptins, or
oscillapeptins and aeruginosins are also known as microcins or spumigins. In the early
literature, the cyanopeptide names are often chosen to refer to the taxon from which the
compound had been isolated from and a suffix is added referring to structural properties
including characteristic residues, molecular weight, or strain number. Further details of some
additional cyanopeptides and their naming systems can be found in comprehensive review on
this matter (Chlipala et al. 2011, Van Wagoner et al. 2007, Welker and von Döhren 2006).

BOX 1. Structural characteristics of selected cyanopeptides.

Microcystins are heptapeptides with the characteristic Adda moiety (i.e., 3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl-deca-4,6-dienoic acid) and variable residues in position (2) and (4). Cyanopeptolins are hexapeptides with the characteristic Ahp moiety (3-amino-6-methoxy-2-piperidone), and are depsipeptides where a β-lactone ring at the threonine introduces an ester bond and share a mostly conserved linear side chain off position (1). Anabaenopeptins are cyclic peptides with a characteristic ureido bond connecting the primary amine of lysine's R-group (5) with the carboxyl group of the neighboring amino acid to form an amide bond. Aerucyclamides are cyclic hexapeptides characterized by three azole or azoline rings, likely derived from cysteine and threonine modification. Aeruginosines are linear tetrapeptides that contain four monomers including the partially substituted Choi moiety (2-carboxy-6-hydroxyoctahydroindole) and Hpla moiety (p-hydroxyphenyl lactic acid) based on tyrosine and often an arginine derivative at the C-terminus. Lastly, microginins are linear peptides with four to six amino acids, one of them being the characteristic Ahda moiety (3-amino-2-hydroxydecanoic acid, or -octanoic acid) and predominantly two tyrosine monomers.




Figure 2. Schematic of representatives for six cyanopeptide classes: Microcystin-LR, Cyanopeptolin A, Anabaenopeptin A, Aerucyclamide A, Aeruginosin KB 676, and Microginin 713. Colored areas in the structure represent variable parts that can be substituted and examples of alternative building blocks are presented below each structure in the respective legend. The stereochemistry is not considered in these representations and annotations were adopted from Welker and Döhren (2006).

3. Occurrence of cyanopeptides during bloom events

The chemical diversity of cyanopeptides is large, but how common are these compounds in surface waters dominated by cyanobacteria? While the abundance of cyanobacteria can be monitored successfully, following cyanobacterial peptides is more challenging because of the variety of potential target compounds. Few studies focused on the presence of cyanopeptides other than microcystins but those that did search further, discovered that microcystins *never* occurred alone. While the ecological benefit for cyanobacteria to produce these complex and metabolically expensive cyanopeptides has not been completely resolved, not even for microcystins, evidence is presented below on their abundance and bioactivity.

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

3.1 Ability of cyanopeptide production

The likelihood of cyanopeptides to occur in the environment depends on the presence of cyanobacteria that carry the genes for toxin production and that these genes are actually expressed. The exposure concentrations of cyanopeptides depend on the abundance of those toxin producers and the cyanopeptide production dynamics as well as the degradation and fate processes of toxins in surface waters.

Genotype analysis can reveal gene clusters that are indicative of the metabolic synthesis pathways for cyanopeptides (Kurmayer et al. 2015, Kurmayer et al. 2011). Cyanopeptide biosynthesis involves multi-enzyme complexes of non-ribosomal peptide synthetases and polyketide synthases that can be conserved across cyanobacterial genomes (Kurmayer et al. 2015, Kurmayer et al. 2011, Neilan et al. 2013). For example, the biosynthetic cluster code and highly conserved multidomain proteins required to produce microcystins have been identified in the genus of Microcystis, Planktothrix, Nostoc, and Dolichospermum (Anabaena) (Christiansen et al. 2003, Kosol et al. 2009, Kurmayer and Christiansen 2009, Merel et al. 2013, Rantala et al. 2004, Rouhiainen et al. 2004, Zikova et al. 2010). Within one species the genes may not always be expressed and also non-producing strains exists that lack the ability to produce microcystins altogether (Bogialli et al. 2017, Briand et al. 2016, Davis et al. 2009, Kurmayer and Christiansen 2009, Kurmayer et al. 2004, Welker and von Döhren 2006). At the same time, one cyanobacterial species can harbor biosynthesis pathways for several cyanopeptides beyond microcystins (Kurmayer and Christiansen 2009, Neilan et al. 2013, Shishido et al. 2017). For example, the biosynthesis genes for microcystins, anabaenopeptins, aeruginosins, microginins, microviridins, and cyanopeptolins were identified in the common cyanobacteria Planktothrix rubescens and P. agardhii as well as in Microcystis sp. from a bloom event in San Francisco Bay (Kurmayer et al. 2016, Otten et al.

2017). Overall, much less genetic information, for example regarding indicative syntheses gene clusters or distribution of non-/producing strains is available for cyanopeptides beyond microcystins. Cyanobacteria often co-occur during bloom events and their genotypes suggest that they are *able* to produce different cyanopeptides but not whether these metabolites are actually produced.

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

225

226

227

228

229

3.2 Production during bloom events.

Chemical analysis verifies that cyanobacteria can indeed use their genetic ability effectively to biosynthesize cyanopeptides during bloom events. A variety of cyanopeptides was frequently detected in lakes, rivers, estuaries, and reservoirs affected by cyanobacteria across the globe including studies in Italy, Greece, Poland, Portugal, Israel, Switzerland, and Finland (Ferranti et al. 2013, Gkelis et al. 2015, Grabowska et al. 2014, Lifshits and Carmeli 2012, Lopes et al. 2012, Rohrlack et al. 2009). Additional studies inspected field isolates, which constitute cyanobacterial cultures isolated from environmental samples and regrown under laboratory conditions. All 26 cyanobacterial isolates from a drinking water reservoir in Portugal produced a range of aeruginosines, anabaenopeptins, and microcystins (Saker et al. 2005). Similar field isolates originating from a Czech reservoir showed up to 90 co-occurring cyanopeptides, from Brazilian surface waters up to 38 cyanopeptides, and nearly 60 cyanopeptides from Baltic Sea isolates (Mazur-Marzec et al. 2016, Sanz et al. 2015, Welker et al. 2006). Advanced analytical techniques further revealed the diverse cyanopetidome on the cellular scale realized by analyzing single bacterial colonies and cyanobacterial filaments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) (Harustiakova and Welker 2017, Welker et al. 2004).

248

249

3.3 Exposure concentrations in surface waters

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

Quantification of cyanopeptides is a key prerequisite to characterize the potential exposure concentrations in surface waters where cyanobacteria proliferate. Most studies, however, only report qualitative information such as frequencies of detection of cyanopeptides, as mentioned above. To date, only few studies quantified absolute concentrations of cyanopeptides beyond microcystins (Figure 3). A recent study quantified three cyanopeptolins, one microginins, two anabaenopeptins, and five microcystins in samples from six eutrophic lakes in the United States (Beversdorf et al. 2017). Another study assessed the aqueous concentrations of five anabaenopeptins, one cyanopeptolin and ten microcystins in European lakes using analytical standards isolated from biomass extracts. Here, all cyanopeptides were detected frequently with 87% for microcystins, 90% for a cyanopeptolin, and 100% for anabaenopeptins (Chorus et al. 2006). Data in Figure 3 show that concentrations were in the μ g/L range (i.e., nanomolar) and microcystins were not always dominating, particularly in the European lakes. The study on European Lakes further showed that cyanopeptide production from one cyanobacterial species can vary between different lakes and only correlates with biovolume of cyanobacteria for some cyanopeptides (Chorus et al. 2006). Furthermore, a recent study of the U.S. Great Lakes Basin demonstrates that the total load of cyanopeptolins and anabaenopeptins entering drinking water treatment plants can be comparable to microcystins and also correlated with abundance of cyanobacteria (cell count, chlorophyll-a) and organic carbon concentrations (UV absorbance, turbidity) (Beversdorf et al. 2018). Such quantitative assessments are rare because of the lack of standard reference materials for most cyanopeptides that would allow to convert a signal from analytical instruments into the absolute mass of a cyanopeptide present in the sample. Currently, reference standards of 12 microcystins (MC-LR, -RR, -YR, -LA, -LF, -LW, -WR, -D-Asp3-LR, D-Asp3-RR, HtyR,

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

HilR) are commercially available and partially included in standardized analytical methods (ISO 20179:2005, US EPA Method 544), which can reach sensitivities in the low nanomolar range (e.g., by liquid chromatography coupled to mass spectrometry). The limited availability of reference standards restricts comprehensive quantification of cyanopeptide concentrations considering that more than 240 microcystin isoforms and many more additional cyanopeptides have been identified (Meriluoto et al. 2017). Organic synthesis was achieved for some linear aeruginosines that also allowed to selectively test the effect of subtle changes of functional moieties, i.e., chloride and sulfate removal (Scherer et al. 2016, Scherer and Gademann 2017). However, organic synthesis is currently not feasible for the structurally more complex cyanopeptides particularly considering the stereochemistry of these molecules. Most commercially available cyanopeptide materials stem from isolation efforts of cyanobacterial biomass, called bioreagents, which do not strictly qualify as reference material because of their lower purity and even certified reference materials come in varying purity and require batch-to-batch verification of the absolute concentration. Without reference standards for each compound of interest, one common alternative is to report semiquantitative concentrations relative to an available standard: microcystin-LR.




Figure 3. Cyanopeptide concentrations (μg/L) for six eutrophic lakes in the United States (top) and four European lakes (bottom) (Beversdorf et al. 2017, Chorus et al. 2006). The boxplot shows data of total cyanopeptides including 4 microcystins (MC-LR, -YR, -LA, -RR), 2 anabaenopeptins (Anabaenopeptin-B, -F) and 2 cyanopeptolins (Cyanopeptolin-1007, -1041) for the U.S. lakes and 10 microcystins (MC-RR, -YR, -LR, -Asp3-RR, -Dha7-RR, -Asp3, -Dhb7-RR, -Asp3-HTyr, 2 unidentified MCs), 5 anabaenopeptins (Anabaenopeptin A,-B, -F, Aeruginosinamide, Oscillamide Y) and 1 cyanopeptolin (Cl-Cyanopeptolin W) for the European lakes. The black line within the boxplot indicates the median value, whiskers indicate 25th and 75th percentiles. For comparison, the average values for total microcystins are shown as green lines within the boxplot. The pie charts present the relative distribution of concentrations for total microcystins (green), anabaenopeptins (orange), and cyanopeptolins (blue) and the sample number (n) is indicated for each lake.

4. Toxicity of cyanopeptides

Considering that other cyanopeptides indeed occur at similar concentrations as microcystins during cyanobacterial bloom events, there is a need to evaluate their potential

(eco)toxicological risk. In the following, first those studies are highlighted that assessed the (sub-)lethal effects for these cyanopeptides. Then, studies are presented that focused on microcystins alone but observation suggest that additional compounds might be present in the cyanobacterial extracts that contributed to toxic effects.

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

306

307

308

309

4.1 (Sub-)lethal effects

One common effect observed for cyanopeptides is the inhibition of enzymes. Particularly, inhibition of proteases has been frequently reported for cyanopeptolins, anabaenopeptins, aeruginosins, and microginins and inhibitory potencies (IC₅₀ values) down to the low nanomolar range, comparable to concentrations observed during bloom events (Figure 4). For cyanopeptolins, anabaenopeptins, and aeruginosins inhibition of human serine proteases involved in blood coagulation was observed, i.e., Factor VIa/VIIa, thrombin, plasmin, and kallikrein (Bonjouklian et al. 1996, Gademann et al. 2010, Hanessian et al. 2006, Kodani et al. 1999, Kohler et al. 2014, Schreuder et al. 2016) and inhibition of pancreatic and leucocyte elastases for cyanopeptolins and anabaenopaptins (Bubik et al. 2008, Sedmak et al. 2008). Further tests with proteases showed inhibition of carboxypeptidases A+B and leucine aminopeptidase involved in food metabolism for cyanopeptolins, anabaenopeptins, and microginins (Ishida et al. 2000a, Ishida et al. 1998, Ishida et al. 1997, Itou et al. 1999, Kodani et al. 1999, Murakami et al. 2000, Walther et al. 2009), inhibition of angiotensin-converting enzymes involved in blood pressure regulation for microginins (Kodani et al. 1999, Okino et al. 1993), and inhibition of trypsin and chymotrypsin activity for cyanopeptolins and aeruginosins (Banker and Carmeli 1999, Bister et al. 2004, Bonjouklian et al. 1996, Gademann et al. 2010, Hanessian et al. 2006, Kodani et al. 1999, Kohler et al. 2014, Raveh and Carmeli 2009, Reshef and Carmeli 2001, Sano and Kaya 1995, Von Elert et al. 2005). Microginins were also observed to inhibit Mycobacterium tuberculosis protein tyrosine

phosphatase (Muller et al. 2006), and aerucyclamides showed activity against leukemia cells and human parasites (Ishida et al. 2000b, Portmann et al. 2008b). Cyanopeptides also show antimicrobial, antifungal and antimycobacterial activity as recently reviewed elsewhere (Swain et al. 2017).

Another common observation is the toxicity against the grazing crustacean *Thamnocephalus platyurus* reported for microcystins, cyanopeptolins, aeruginosins, microginin, and aerucyclamides with LC₅₀ values in the low micromolar range (mg/L) (*Blom et al. 2003, Blom et al. 2001, Bober and Bialczyk 2017, Gademann et al. 2010, Kohler et al. 2014, Portmann et al. 2008a, Portmann et al. 2008b). While the observed concentrations in lake water were one order of magnitude lower (Figure 3), much higher exposure concentration must be expected for organisms that feed directly on cyanobacterial cells by ingestion of biomass and also when human swallow contaminated water or inhale cells with aerosols. The hypothesis that cyanobacteria produce these complex molecules to defend themselves against predators is in line with observed toxicity against grazers and a promising avenue to further explore in future mechanistic studies. Cyanopeptides have been detected in tissue of exposed fish, frogs, snails, and mussels but the toxicokinetics of internal distribution and bioaccumulation is not completely understood (Gkelis et al. 2006).*

4.2 Toxicity of microcystins and beyond

Microcystins are hepatotoxins that can enter liver cells by hitchhiking a specific membrane transporter, i.e., organic anionic transporting polypeptide (Fischer et al. 2005). Once in the liver cell, microcystins suppress enzyme activities by binding to protein phosphatases (PP1 and PP2), which causes dysregulation, formation of reactive oxygen species, and eventually liver failure (Ding et al. 2000, Honkanen et al. 1990, Konst et al. 1965, Mackintosh et al. 1990). The toxicity depends critically on the microcystin variant, the

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

exposure route, and the target organisms. For example, the lethal dose to kill 50% of mice (acute LD₅₀) ranges between 5,000-10,000 µg/kg for oral and 50 µg/kg for intraperitoneal administration (Kuiper-Goodman et al. 1999). Epidemiological studies indicate human health effects and potential cancer development from acute and chronic exposure to cyanopeptides as recently reviewed (Liu et al. 2017, Svircev et al. 2017). Some toxicological studies on microcystins offer clues concerning the potential toxicity of other cyanopeptides. These studies did not include other cyanopeptides specifically but hint towards their toxicity when (a) the observed toxic effects exceeded the toxicity expected from microcystins alone or (b) the symptoms could not be associated with microcystins. One example is the case of human exposure to cyanotoxins by recreational activities. Here, the concurrence of illness was correlated with cyanobacterial cell number but vomiting, diarrhea, and flu-symptoms and could not directly be associated with the presence of known liver toxins (microcystins) or neurotoxins (e.g., saxitoxin, anatoxin) (Berg et al. 2011, Pilotto et al. 1997). Other studies compared microcystin-producing strains (wild-type) with cyanobacterial strains that specifically cannot produce microcystins (knock-out mutants). For example, while only the microcystin producing strain had lethal effects on crustaceans (Daphnia geleata, D. magna), also the non-producing strain caused decreased ingestion rates, increased enzyme production involved in biotransformation, and altered reproductive processes, suggesting that compounds other than microcystins also affect aquatic organisms (Dao et al. 2013, Hulot et al. 2012, Rohrlack et al. 1999). Additional studies frequently observed that extracts from the microcystin knock-out mutants also caused adverse effects on aquatic organisms and cell lines (Baumann and Juttner 2008, Best et al. 2001, Dao et al. 2013, Fastner et al. 2003, Hulot et al. 2012, Keil et al. 2002, Liang et al. 2017, Smutna et al. 2014). For example, the formation of oedema and bent tails in zebrafish larvae and dysregulation in fish were observed also upon exposure to extracts of non-microcystin-producing cyanobacteria (Keil et

al. 2002, Le Manach et al. 2016). Information on the toxicity of some additional cyanopeptides including cryptophycins, tolytoxin, scytophycins, and microviridins can be found elsewhere (Chlipala et al. 2011).




Figure 4. Ranges of inhibitory concentrations of enzymes, IC₅₀ values (μg/L) for the different cyanopeptide classes including proteases (blue) (Banker and Carmeli 1999, Bister et al. 2004, Bonjouklian et al. 1996, Gademann et al. 2010, Hanessian et al. 2006, Ishida et al. 1998, Ishida et al. 1997, Itou et al. 1999, Kodani et al. 1999, Kohler et al. 2014, Murakami et al. 2000, Okino et al. 1993, Raveh and Carmeli 2009, Reshef and Carmeli 2001, Sano and Kaya 1995, Schreuder et al. 2016, Von Elert et al. 2005, Walther et al. 2009), phosphatases (purple) (An and Carmichael 1994, Honkanen et al. 1990) and others (red) (Ishida et al. 2000b, Muller et al. 2006, Portmann et al. 2008b) and the lethal concentrations, LC₅₀ values (μg/L) for the grazing crustacean *Thannocephalus platyurus* (green) (Blom et al. 2001, Bober and Bialczyk 2017, Gademann and Portmann 2008, Kohler et al. 2014, Portmann et al. 2008a, Portmann et al. 2008b, Scherer et al. 2016). Note break in x-axis, hereafter 1k represents 1,000 μg/L.

5. Implications for risk assessment

The key challenge for future risk assessment of cyanobacterial peptides is the need to cover a large chemical and biological space. Implications and research needs for analytical methods, assessment of abundant and persistent peptides, as well as toxic peptides to prioritize relevant cyanotoxins are discussed in the following (Figure 5).

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

397

398

399

400

401

5.1 Analytical Methods

Hundreds of cyanopetides have been structurally identified and the lack of reference standard materials and comprehensive databases of all cyanopeptides are the key challenges for standardized and sensitive analytical detection. High-resolution tandem mass spectrometry (HRMS/MS) has become more widely available in the scientific research institutions, regulatory laboratories, and even at larger water treatment utilities. While HRMS/MS analysis alone is not sufficient for structurally elucidating newly identified compounds, it can be directed to specifically detect and differentiate structurally known cyanopeptides. So-called suspects screening with HRMS/MS allows to identify cyanopeptides without available reference materials based on the exact mass (m/z), presence of one or more charge states (z=1, 2 etc.), expected isotope pattern and common adducts (e.g., +H, +Na, +NH₄) as well as secondary fragmentation (MS2) following procedures established for small organic pollutants and their transformation products (Krauss et al. 2010, Schymanski et al. 2014). Those cyanopeptide that are structurally known comprise the suspect list in this scenario. The high resolving power and mass spectral accuracy is essential for a reliable assignment of exact mass of a cyanopeptide. Other than for small organic molecules, most cyanopeptides are large molecules and automated chemical formula assignment is often not reliable for identification. To increase the confidence of the identification, the secondary fragmentation pattern can be matched with in-silico predictions

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

and literature information. Because we also face isobaric compounds one needs to obtain fragmentation spectra that are unambiguously identifying a single cyanopeptide, e.g., due to unique fragments. For reliable and faster cyanopeptide identification, a public spectral library should be built and maintain by collaborative efforts of the scientific community. The use of extracts of pure cyanobacterial laboratory cultures may serve as qualitative reference materials for the identification of cyanopeptide in field samples. For example, when the dominating cyanobacterial species in a water body are known, the field samples can be compared to the extract of the respective cyanobacterial species from laboratory culture. This approach would allow to compare not only the spectral fragmentation but also the retention behaviour during chromatographic separation (retention time match). With such diagnostic evidence, cyanopeptides can be identified as the "probable structure" even without reference standards available (Level 2 after Schymanski et al. 2014). While identification of cyanopeptide is possible with conclusive HRMS/MS data, the quantification without certified reference standards presents another critical challenge. Analytical chemistry widely relies on semi-quantitative exposure concentrations thus far, for example by microcystin-LR-equivalent concentrations for all cyanopeptides. One avenue to explore can be a class-specific semi-quantitative equivalent approach that uses representative reference material of one abundant and potentially toxic cyanopeptides of each class. However, even among microcystin variants, the analytical response can vary by a multitude, due to different response factors in mass spectrometry, which leads to higher uncertainties when relying on equivalent concentrations. Because variants of a cyanopeptide class vary only in a limited number of moieties, a structure-based prediction of response factors for variants of a cyanopeptide class would be one possible avenue to explore. In the case of electronspray ionization mass spectrometry (ESI-MS), commonly employed to analyse cyanopeptides, the response factor comprises how well a structural moiety can be ionized,

which depends on instrumental parameters (source settings, mobile phase composition, pH etc.), on physico-chemical properties of the analyte, and matrix-specific interferences. For example, the ionization of microcystins in ESI-MS depends largely on the presence of basic, ionizable arginine moieties (Yuan et al. 1999) but can also be greatly affected by polarity, and vaporability of the target compounds (Kiontke et al. 2016). In silico tools have been used in proteomic research to prioritize the best ionizable, i.e., best observable proteolytic peptides for target proteins based on the primary sequence of linear peptides (Matsuda et al. 2017). However, such prediction becomes more complex with the stereochemistry of cyanopeptides particularly for cyclic structures (Wang and Cole 1994) and in presence of sample matrix from biomass extracts, e.g., ion suppression (Kankaanpaeae et al. 2009, Karlsson et al. 2005). While these quantification methods may be sufficient to screen for general presence of cyanopeptide and tentative abundance, reference standard materials of those cyanopeptide of toxicological concern are ultimately required.

5.2 Abundant and persistent peptides

To make future risk assessment of cyanopeptides more manageable, one approach is to assess the number of tentatively relevant compounds based on exposure concentrations by prioritizing those compounds that are produced in considerable amounts by common cyanobacteria. Peptide profiles can be assessed and curated for common strains in comprehensive archives and compared across geographic and temporal trends. When the major cyanobacterial strains in a bloom event are identified, one can explore whether the expected cyanopeptides can be predicted based on archived peptide profiles from laboratory cultures and field isolates. While current literature suggests that only a smaller subset of cyanopeptides is expected at an individual site, this may still comprise dozens of compounds.

Among the abundant cyanopeptides, those that are persistent could be further prioritized
for risk assessment. Here, both persistence in environmental and engineered systems is of
interest. Environmental fate studies include biodegradability as well as mass transfer,
complexation, abiotic hydrolysis, and photochemical transformation processes. Microcystins
are susceptible to microbial degradation and photochemical transformation but can still
persist in water for several days or weeks (de la Cruz et al. 2011, Edwards et al. 2008,
Sharma et al. 2012, Walker 2014). While open questions regarding the behavior of
microcystins remain, essentially no information currently exists on the fate of the other
cyanopeptides.
The relatively long half-life of microcystins in surface waters suggest that cyanopeptides
can reach water treatment plants influents when blooms occur in freshwater reservoirs.
Consequently, the engineered processes need to be inspected for their ability to remove
cyanopeptides by conventional treatment including sand and activated carbon filtration as
cyanopeptides by conventional treatment including sand and activated carbon filtration as
cyanopeptides by conventional treatment including sand and activated carbon filtration as well as advanced oxidation processes including UV/H_2O_2 , ozonation, and membrane
cyanopeptides by conventional treatment including sand and activated carbon filtration as well as advanced oxidation processes including UV/H ₂ O ₂ , ozonation, and membrane filtration. All treatment options need to consider that intracellular toxins can be released by

drinking waters (Carmichael 2000, Hoeger et al. 2005, Miller et al. 2017) avoiding the intake

of contaminated water and developing adoptive treatment strategies during bloom events

needs to be considered for impacted source waters. Overall, the fate and transformation

behavior of cyanopeptides will define the exposure concentrations after release from the

bacterial cells that need to be considered for risk assessment.

5.3 Toxic peptides

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

In addition to chemical analysis, effect-based tests are needed in the process of prioritizing cyanopeptides. First, the most abundant and persistent compounds might not be the most toxic. Second, not all cyanopeptides might be structurally known and would be missed in a suspect screening by HRMS/MS as described above. In addition, toxicological analysis is promising to investigate mixture toxicities of co-occurring cyanopeptides. To identify and quantify the main toxicological effects of one cyanopeptide, one can focus on a targeted approach with a specific hypothesis for the toxic mode of action or effect-based analysis by screening various endpoints. The hypothesis-driven approach is challenged by the lack of information about potential target sites of these cyanopeptides. We currently lack a clear understanding of internal distribution and internal concentrations of the cyanopeptides. In the case of microcystins, they do not only cause liver toxicity but have also been reported to induce neurological symptoms in exposed patients (Hu et al. 2016). Also, the organic anion transporting polypeptides (OATP), which mediate the cellular uptake of microcystins, are not only expressed in the liver but also at the blood brain barrier (Fischer et al. 2005). A better understanding of the exposure routes can further guide which tissue will be in contact with cyanopeptides, for example via aerosol inhalation and swallowing contaminated water. The current literature demonstrates that cyanopeptides inhibit different target enzymes compared to microcystins, which needs to be considered when selecting toxicity tests. Hence, not only liver, but also the brain, gill/lung and gut are among the plausible target organs to investigate. In addition to the challenge that we are dealing with hundreds of cyanopeptides, also many

possible toxic modes of action need to be considered. High-throughput toxicity screening can be a powerful approach to sieve through thousands of potential endpoints. High-throughput toxicity screening uses in vitro toxicity assays and is being used extensively for testing the effects of chemicals and their mixtures in risk assessment and drug discovery (Szymanski et

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

al. 2012). Cellular assays that measure defined toxic endpoints in automated and miniaturized systems present an opportunity to overcome the bottle neck of extremely low throughput in conventional in vivo tests. However, toxicity can not only be toxin-specific but also cellspecific, individual cellular models can not cover all possible toxic mechanisms, processes that rely on cellular communication, and control systems throughout the organisms (Astashkina et al. 2012). Transcriptomic analysis offers another holistic approach to predict potential adverse effects and molecular mechanisms considering the whole organism. For example, a reduced transcriptome atlas of the zebrafish was investigated for 74 chemicals including microcystin-LR and cyanopeptolin-1020 revealing their effects on early neuronal development (Zhang and Zhao 2018). The transcriptomics approach can help characterize and quantify unanticipated toxic effects but the relationship between gene expression and toxic mechanisms still needs to better understood and annotating the function of genes of organisms with ecological relevance is still limited (Schirmer et al. 2010). In the future, advanced data processing and mechanistic understanding, and reduced costs may enable the wider use of transcriptomic screening for the risk assessment of cyanopeptides. These screening approaches can also be used for crude cyanobacterial extracts without identifying each cyanopeptide first. The chemical demand of several mg for comprehensive toxicity tests are high compared to chemical analysis where even a few μg can be sufficient. Hence, bioactive screening of complex extracts can be attractive to delineate potential toxic sample early on. When an effect is observed, fractionation of extracts allows to further curtail the origin of a toxic effect but only isolation efforts of a single compound can yield clarity about toxic potencies of one specific cyanopeptide. The risk assessment for cyanotoxins can learn from development in drug discovery that uses high-throughput screening in

combination with in silico modelling for toxicity but also for adsorption, distribution,

metabolism, and excretion (van de Waterbeemd and Gifford 2003). In silico models rely on

molecular modelling of the potential interaction of compound with a target site, e.g., an enzyme, as well as data modelling including structure-activity relationships. Once a target site has been identified for one cyanopeptide, the molecular mechanism of toxicity and quantitative structure activity relationships can be further explored for other variants in the cyanopeptide class. For example, the binding affinities to carboxypeptidase has been recently modelled for a range of anabaenopeptins (Walther et al. 2009). Also, the development of antibodies should be explored in the future to allow for quantification of total cyanopeptide of one class analogous to the enzyme-linked immunosorbent assay (ELISA) existing for microcystins.

The combined approach of chemical and effect-based screening aims for an informed decision about the tentatively abundant, persistent, and toxic cyanopeptides to make a comprehensive risk assessment more manageable. In the process of prioritizing cyanopeptide for risk assessment, additional factors may be decisive, for example the value of a field site harbouring particularly sensitive organisms, impacts on natural resource utilization and water treatment options, or recreational values, which represent different personal and public interests, priorities for human and ecological health.




Figure 5. Strategy for a prevalence studies to reduce the large number of theoretically known cyanopeptides to be a priority candidate list for risk assessment of tentatively abundant, persistent, and toxic compounds. One prerequisite is a state-of-the art analytical method for sensitive and standardized identification of cyanopeptides including comprehensive, open-access databases for all structurally known cyanopeptides (i.e., suspects) and spectral libraries for suspect screening by high-resolution mass spectrometry (HRMS/MS). The abundant peptide can be identified by peptide profiling of common cyanobacterial strains from laboratory cultures and in-situ bloom samples. Fate studies in will point to the most persistent peptides in environmental and engineered systems (e.g. drinking water treatment). The bioactivity screening including *in vitro* assays and transcriptomics can inform about the mode of action across different compounds or compound classes from fractionated extracts containing mixtures of toxins and isolated compounds. The potentially abundant, persistent, and toxic cyanopeptides are the priority candidates for future risk assessments.

6. Conclusions

The current state of the literature supports that cyanopeptides are bioactive and produced in legions at comparable frequency as microcystins in surface waters that are impacted by cyanobacteria. Consequently, risk assessment of cyanopeptides beyond microcystins and their mixtures is necessary. The few studies that quantified cyanopeptides beyond microcystins find that they can reach comparable concentrations and complementary studies are desired to verify these phenomena for different surface waters, dominating cyanobacterial species, and bloom dynamics. Also, additional toxicity studies are needed that target human and ecosystem health with relevant exposure scenarios. The key challenge is the need to cover a large chemical and biological space for risk assessment without essential reference standards for the hundreds of known cyanopeptides. To move forward from here, advanced analytical methods to identify and quantify cyanopeptides need to be used to determine toxin profiles in field samples and laboratory strains, to assess their fate and transformation processes, and to screen for their potential bioactivity. Such prevalence study could reveal the priority candidates among cyanopeptides and their mixtures for which a comprehensive risk

assessment will be more manageable (Figure 5). The combined approach of chemical and
effect-based screening aims for an informed decision about the tentatively abundant,
persistent, and toxic cyanopeptides to make a comprehensive risk assessment more
manageable. In the process of prioritizing cyanopeptides for risk assessment, additional
factors may be decisive, for example the value of a field site harbouring particularly sensitive
organisms, impacts on natural resource utilization and water treatment options, or
recreational values, which represent different personal and public interests, priorities for
human and ecological health.

Acknowledgments

Funding of the Marie Curie Innovative Training Network "Natural Toxins and Drinking Water Quality—From Source to Tap (NaToxAq)" (Grant No. 722493) by the European Commission is gratefully acknowledged. I thank Dr. Kathrin Fenner, Dr. Juliane Hollender, Dr. Christian Stamm (Eawag), and Pavel Babica (Masaryk University) for fruitful discussions, Todd Miller (University of Wisconsin) and Jutta Fastner (German Environment Agency) for providing raw data from previous publications, and anonymous reviewers for productive feedback.

References

An, J.S. and Carmichael, W.W. (1994) Use of a Colorimetric Protein Phosphatase Inhibition
Assay and Enzyme-Linked-Immunosorbent-Assay for the Study of Microcystins and
Nodularins. Toxicon 32(12), 1495-1507.

615	Astashkina, A., Mann, B. and Grainger, D.W. (2012) A critical evaluation of in vitro cell
616	culture models for high-throughput drug screening and toxicity. Pharmacology &
617	Therapeutics 134(1), 82-106.
618	
619	Banker, R. and Carmeli, S. (1999) Inhibitors of serine proteases from a waterbloom of the
620	cyanobacterium Microcystis sp. Tetrahedron 55(35), 10835-10844.
621	
622	Baumann, H.I. and Juttner, F. (2008) Inter-annual stability of oligopeptide patterns of
623	Planktothrix rubescens blooms and mass mortality of Daphnia in Lake Hallwilersee.
624	Limnologica 38(3-4), 350-359.
625	
626	Berg, K.A., Lyra, C., Niemi, R.M., Heens, B., Hoppu, K., Erkomaa, K., Sivonen, K. and
627	Rapala, J. (2011) Virulence genes of Aeromonas isolates, bacterial endotoxins and
628	cyanobacterial toxins from recreational water samples associated with human health
629	symptoms. J. Water Health 9(4), 670-679.
630	
631	Best, J.H., Eddy, F.B. and Codd, G.A. (2001) Effects of purified microcystin-LR and cell
632	extracts of Microcystis strains PCC 7813 and CYA 43 on cardiac function in brown trout
633	(Salmo trutta) alevins. Fish Physiol. Biochem. 24(3), 171-178.
634	
635	Beversdorf, L.J., Rude, K., Weirich Chelsea, A., Bartlett Sarah, L., Seeman, M., Kozik, C.,
636	Biese, P., Gosz, T., Suha, M., Stempa, C., Shaw, C., Hedman, C., Piatt, J. and Miller
637	Todd, R. (2018) Analysis of cyanobacterial matebolites in surface water and raw
638	drinking waters reveals more than microcystin. Water Research in press.
639	

640	Beversdorf, L.J., Weirich Chelsea, A., Miller Todd, R. and Bartlett Sarah, L. (2017) Variable
641	Cyanobacterial Toxin and Metabolite Profiles across Six Eutrophic Lakes of Differing
642	Physiochemical Characteristics. Toxins (Basel) 9(2).
643	
644	Bister, B., Keller, S., Baumann Heike, I., Nicholson, G., Weist, S., Jung, G., Sussmuth
645	Roderich, D. and Juttner, F. (2004) Cyanopeptolin 963A, a chymotrypsin inhibitor of
646	Microcystis PCC 7806. Journal of Natural Products 67(10), 1755-1757.
647	
648	Blom, J.F., Bister, B., Bischoff, D., Nicholson, G., Jung, G., Sussmuth, R.D. and Juttner, F.
649	(2003) Oscillapeptin J, a new grazer toxin of the freshwater cyanobacterium Planktothrix
650	rubescens. Journal of Natural Products 66(3), 431-434.
651	
652	Blom, J.F., Robinson, J.A. and Juttner, F. (2001) High grazer toxicity of [D-Asp(3) (E)-
653	Dhb(7)]microcystin-RR of Planktothrix rubescens as compared to different microcystins.
654	Toxicon 39(12), 1923-1932.
655	
656	Bober, B. and Bialczyk, J. (2017) Determination of the toxicity of the freshwater
657	cyanobacterium Woronichinia naegeliana (Unger) Elenkin. J. Appl. Phycol. 29(3), 1355-
658	1362.
659	
660	Bogialli, S., Bortolini, C., Di Gangi, I.M., Di Gregorio, F.N., Lucentini, L., Favaro, G. and
661	Pastore, P. (2017) Liquid chromatography-high resolution mass spectrometric methods
662	for the surveillance monitoring of cyanotoxins in freshwaters. Talanta 170, 322-330.
663	

664	Bonjouklian, R., Smitka, T.A., Hunt, A.H., Occolowitz, J.L., Perun, T.J., Doolin, L.,
665	Stevenson, S., Knauss, L., Wijayaratne, R., Szewczyk, S. and Patterson, G.M.L. (1996)
666	A90720A, a serine protease inhibitor isolated from a terrestrial blue-green alga
667	Microchaete loktakensis. Tetrahedron 52(2), 395-404.
668	
669	Briand, E., Bormans, M., Briand, E., Gerwick William, H., Gugger, M., Dorrestein Pieter, C.,
670	Dorrestein Pieter, C. and Gerwick William, H. (2016) Changes in secondary metabolic
671	profiles of Microcystis aeruginosa strains in response to intraspecific interactions.
672	Environmental Microbiology 18(2), 384-400.
673	
674	Bubik, A., Sedmak, B., Novinec, M., Lenarcic, B. and Lah, T.T. (2008) Cytotoxic and
675	peptidase inhibitory activities of selected non-hepatotoxic cyclic peptides from
676	cyanobacteria. Biological Chemistry 389(10), 1339-1346.
677	
678	Bucheli, T.D. (2014) Phytotoxins: Environmental Micropollutants of Concern?
679	Environmental Science & Technology 48(22), 13027-13033.
680	
681	Carmichael, W.W. (2000) Assessment of Blue-Green Algal Toxins in Raw and Finished
682	Drinking Water; AWWA Research Foundation and American Water Works Association:
683	Denver, CO, USA.
684	
685	Carmichael, W.W., Azevedo, S.M.F.O., An, J.S., Molica, R.J.R., Jochimsen, E.M., Lau, S.,
686	Rinehart, K.L., Shaw, G.R. and Eaglesham, G.K. (2001) Human fatalities from
687	cyanobacteria: Chemical and biological evidence for cyanotoxins. Environ. Health
688	Perspect. 109(7), 663-668.

689	
690	Chlipala, G.E., Mo, S. and Orjala, J. (2011) Chemodiversity in freshwater and terrestrial
691	cyanobacteria - a source for drug discovery. Curr. Drug Targets 12(11), 1654-1673.
692	
693	Chorus, I., Sivonen, K., Codd, G.A., Börner, T., Von Doehren, H., Welker, M., Dittmann, E.
694	Claussner, Y., Christopffersen, K., Schober, E., Utkilen, H., Rohrlack, T., Lyck, S.,
695	Visser, P.M., Tonk, L., Dietrich, D.R., Hoeger, S.J., Tandeau de Marsac, N., Iteman, I.
696	Niesel, V., Fastner, J., Grummt, T., Heinze, R., Ferreira, AH., Warming-Svendsen, T.
697	Flieger, I., Wessel, G., Rouhiainen, L. and Morrison, L.F. (2006) Toxic and Bioactive
698	Peptides in Cyanobacteria - PEPCY Report. https://ec.europa.eu/research/quality-of-
699	life/ka4/pdf/report_pepcy_en.pdf.
700	
701	Christiansen, G., Fastner, J., Erhard, M., Borner, T. and Dittmann, E. (2003) Microcystin
702	biosynthesis in Planktothrix: Genes, evolution, and manipulation. Journal of
703	Bacteriology 185(2), 564-572.
704	
705	Dao, T.S., Ortiz-Rodriguez, R., Do-Hong, L.C. and Wiegand, C. (2013) Non-microcystin and
706	non-cylindrospermopsin producing cyanobacteria affect the biochemical responses and
707	behavior of Daphnia magna. Int. Rev. Hydrobiol. 98(5), 235-244.
708	
709	Davis, T.W., Berry, D.L., Boyer, G.L. and Gobler, C.J. (2009) The effects of temperature and
710	nutrients on the growth and dynamics of toxic and non-toxic strains of microcystis
711	during cyanobacteria blooms. Harmful Algae 8(5), 715-725.
712	

713	de la Cruz, A.A., Antoniou, M.G., Hiskia, A., Pelaez, M., Song, W.H., O'Shea, K.E., He
714	X.X. and Dionysiou, D.D. (2011) Can We Effectively Degrade Microcystins? -
715	Implications on Human Health. Anti-Cancer Agents in Medicinal Chemistry 11(1), 19-
716	37.
717	
718	Ding, WX., Shen, HM. and Ong, CN. (2000) Critical role of reactive oxygen species and
719	mitochondrial permeability transition in microcystin-induced rapid apoptosis in rate
720	hepatocytes. Hepatology (Philadelphia) 32(3), 547-555.
721	
722	Edwards, C., Graham, D., Fowler, N. and Lawton, L.A. (2008) Biodegradation of
723	microcystins and nodularin in freshwaters. Chemosphere 73(8), 1315-1321.
724	
725	Fastner, J., Heinze, R., Humpage, A.R., Mischke, U., Eaglesham, G.K. and Chorus, I. (2003)
726	Cylindrospermopsin occurrence in two German lakes and preliminary assessment of
727	toxicity and toxin production of Cylindrospermopsis raciborskii (Cyanobacteria) isolates
728	Toxicon 42(3), 313-321.
729	
730	Ferranti, P., Fabbrocino, S., Chiaravalle, E., Bruno, M., Basile, A., Serpe, L. and Gallo, P.
731	(2013) Profiling microcystin contamination in a water reservoir by MALDI-TOF and
732	liquid chromatography coupled to Q/TOF tandem mass spectrometry. Food Res. Int.
733	54(1), 1321-1330.
734	
735	Fischer, W.J., Altheimer, S., Cattori, V., Meier, P.J., Dietrich, D.R. and Hagenbuch, B.
736	(2005) Organic anion transporting polypeptides expressed in liver and brain mediate
737	uptake of microcystin. Toxicol. Appl. Pharmacol. 203(3), 257-263.

738	
739	Flores, C. and Caixach, J. (2015) An integrated strategy for rapid and accurate determination
740	of free and cell-bound microcystins and related peptides in natural blooms by liquid
741	chromatography-electrospray-high resolution mass spectrometry and matrix-assisted
742	laser desorption/ionization time-of-flight/time-of-flight mass spectrometry using both
743	positive and negative ionization modes. J. Chromatogr. A 1407, 76-89.
744	
745	Gademann, K. and Portmann, C. (2008) Secondary metabolites from cyanobacteria: Complex
746	structures and powerful bioactivities. Curr. Org. Chem. 12(4), 326-341.
747	
748	Gademann, K., Portmann, C., Blom, J.F., Zeder, M. and Juttner, F. (2010) Multiple Toxin
749	Production in the Cyanobacterium Microcystis: Isolation of the Toxic Protease Inhibitor
750	Cyanopeptolin 1020. J. Nat. Prod. 73(5), 980-984.
751	
752	Gkelis, S., Lanaras, T. and Sivonen, K. (2006) The presence of microcystins and other
753	cyanobacterial bioactive peptides in aquatic fauna collected from Greek freshwaters.
754	Aquat. Toxicol. 78(1), 32-41.
755	
756	Gkelis, S., Lanaras, T. and Sivonen, K. (2015) Cyanobacterial toxic and bioactive peptides in
757	freshwater bodies of Greece: concentrations, occurrence patterns, and implications for
758	human health. Mar. Drugs 13(10), 6319-6335.
759	
760	Grabowska, M., Kobos, J., Torunska-Sitarz, A. and Mazur-Marzec, H. (2014) Non-ribosomal
761	peptides produced by Planktothrix agardhii from Siemianowka Dam Reservoir SDR
762	(northeast Poland). Arch. Microbiol. 196(10), 697-707.

763	
764	Hanessian, S., Del Valle, J.R., Xue, Y. and Blomberg, N. (2006) Total Synthesis and
765	Structural Confirmation of Chlorodysinosin A. J. Am. Chem. Soc. 128(32), 10491-
766	10495.
767	
768	Harustiakova, D. and Welker, M. (2017) Chemotype diversity in Planktothrix rubescens
769	(cyanobacteria) populations is correlated to lake depth. Environ. Microbiol. Rep. 9(2),
770	158-168.
771	
772	Herbert, R.B. and Holliman, F.G. (1964) Aeruginosin B, a naturally occurring
773	phenazinesulfonic acid. Proc. Chem. Soc., London (Jan.), 19.
774	
775	Hoeger, S.J., Hitzfeld, B.C. and Dietrich, D.R. (2005) Occurrence and elimination of
776	cyanobacterial toxins in drinking water treatment plants. Toxicology and Applied
777	Pharmacology 203(3), 231-242.
778	
779	Holliman, F.G. (1969) Pigments of pseudomonas species. I. Structure and synthesis of
780	aeruginosin A. J. Chem. Soc. C (18), 2514-2516.
781	
782	Honkanen, R.E., Zwiller, J., Moore, R.E., Daily, S.L., Khatra, B.S., Dukelow, M. and
783	Boynton, A.L. (1990) Characterization of Microcystin-Lr, a Potent Inhibitor of Type-1
784	and Type-2a Protein Phosphatases. Journal of Biological Chemistry 265(32), 19401-
785	19404.
786	Hu, Y.F., Chen, J., Fan, H.H., Xie, P. and He, J. (2016) A review of neurotoxicity of
787	microcystins. Environ. Sci. Pollut. Res. 23(8), 7211-7219.

788	
789	Hulot, F.D., Carmignac, D., Legendre, S., Yepremian, C. and Bernard, C. (2012) Effects of
790	microcystin-producing and microcystin-free strains of Planktothrix agardhii on long-term
791	population dynamics of Daphnia magna. Annales De Limnologie-International Journal
792	of Limnology 48(3), 337-347.
793	
794	Ibelings, B.W., Backer, L.C., Kardinaal, W.E.A. and Chorus, I. (2014) Current approaches to
795	cyanotoxin risk assessment and risk management around the globe. Harmful Algae 40,
796	63-74.
797	
798	Ishida, K., Kato, T., Murakami, M., Watanabe, M. and Watanabe, M.F. (2000a) Microginins,
799	zinc metalloprotease inhibitors from the cyanobacterium Microcystis aeruginosa.
800	Tetrahedron 56(44), 8643-8656.
801	
802	Ishida, K., Matsuda, H. and Murakami, M. (1998) Four new microginins, linear peptides
803	from the cyanobacterium microcystis aeruginosa. Tetrahedron 54(44), 13475-13484.
804	
805	Ishida, K., Matsuda, H., Murakami, M. and Yamaguchi, K. (1997) Microginins 299-A and -
806	B, leucine aminopeptidase inhibitors from the canobacterium Microcystis aeruginosa
807	(NIES-299). Tetrahedron 53(30), 10281-10288.
808	
809	Ishida, K., Nakagawa, H. and Murakami, M. (2000b) Microcyclamide, a cytotoxic cyclic
810	hexapeptide from the cyanobacterium Microcystis aeruginosa. Journal of Natural
811	Products 63(9), 1315-1317.
812	

813	Itou, Y., Ishida, K., Shin, H.J. and Murakami, M. (1999) Oscillapeptins A to F, serine
814	protease inhibitors from the three strains of Oscillatoria agardhii. Tetrahedron 55, 6871-
815	6882.
816	
817	Jancula, D., Strakova, L., Sadilek, J., Marsalek, B. and Babica, P. (2014) Survey of
818	cyanobacterial toxins in Czech water reservoirs-the first observation of neurotoxic
819	saxitoxins. Environ. Sci. Pollut. Res. 21(13), 8006-8015.
820	
821	Kankaanpaeae, H.T., Sjoevall, O., Huttunen, M., Olin, M., Karlsson, K., Hyvaerinen, K.,
822	Sneitz, L., Haerkoenen, J., Sipiae, V.O. and Meriluoto, J.A.O. (2009) Production and
823	sedimentation of peptide toxins nodularin-R and microcystin-LR in the northern Baltic
824	Sea. Environ. Pollut. (Oxford, U. K.) 157(4), 1301-1309.
825	
826	Karlsson, K.M., Spoof, L.E.M. and Meriluoto, J.A.O. (2005) Quantitative LC-ESI-MS
827	analyses of microcystins and nodularin-R in animal tissue - Matrix effects and method
828	validation. Environ. Toxicol. 20(3), 381-389.
829	
830	Keil, C., Forchert, A., Fastner, J., Szewzyk, U., Rotard, W., Chorus, I. and Kratke, R. (2002)
831	Toxicity and microcystin content of extracts from a Planktothrix bloom and two
832	laboratory strains. Water Res. 36(8), 2133-2139.
833	
834	Kiontke, A., Oliveira-Birkmeier, A., Opitz, A. and Birkemeyer, C. (2016) Electrospray
835	Ionization Efficiency Is Dependent on Different Molecular Descriptors with Respect to
836	Solvent pH and Instrumental Configuration. PLoS One 11(12).
837	

838	Kodani, S., Suzuki, S., Ishida, K. and Murakami, M. (1999) Five new cyanobacterial peptides
839	from water bloom materials of lake Teganuma (Japan). FEMS Microbiol. Lett. 178(2),
840	343-348.
841	
842	Kohler, E., Grundler, V., Haeussinger, D., Kurmayer, R., Gademann, K., Pernthaler, J. and
843	Blom, J.F. (2014) The toxicity and enzyme activity of a chlorine and sulfate containing
844	aeruginosin isolated from a non-microcystin-producing Planktothrix strain. Harmful
845	Algae 39, 154-160.
846	
847	Konst, H., Mckercher, P.D., Gorham, P.R., Robertson, A. and Howell, J. (1965) Symptoms
848	and Pathology Produced by Toxic Microcystis Aeruginosa Nrc-1 in Laboratory and
849	Domestic Animals. Canadian Journal of Comparative Medicine and Veterinary Science
850	29(9), 221
851	
852	Kosol, S., Schmidt, J. and Kurmayer, R. (2009) Variation in peptide net production and
853	growth among strains of the toxic cyanobacterium Planktothrix spp. Eur. J. Phycol.
854	44(1), 49-62.
855	
856	Krauss, M., Singer, H. and Hollender, J. (2010) LC-high resolution MS in environmental
857	analysis: from target screening to the identification of unknowns. Anal. Bioanal. Chem.
858	397(3), 943-951.
859	
860	Kuiper-Goodman, T., Falconer, I. and Fitzgerald, J. (1999) Toxic Cyanobacteria in Water: A
861	Guide to Their Public Health Consequences, Monitoring and Management, pp. pp. 113-
862	154., London.

863	
864	Kurmayer, R., Blom, J.F., Deng, L. and Pernthaler, J. (2015) Integrating phylogeny
865	geographic niche partitioning and secondary metabolite synthesis in bloom-forming
866	Planktothrix. Isme J. 9(4), 909-921.
867	
868	Kurmayer, R. and Christiansen, G. (2009) The Genetic Basis of Toxin Production in
869 870	Cyanobacteria. Freshwater Reviews 2(1), 31-50.
871	Kurmayer, R., Christiansen, G., Fastner, J. and Borner, T. (2004) Abundance of active and
872	inactive microcystin genotypes in populations of the toxic cyanobacterium Planktothrix
873	spp. Environmental Microbiology 6(8), 831-841.
874	
875	Kurmayer, R., Deng, L. and Entfellner, E. (2016) Role of toxic and bioactive secondary
876	metabolites in colonization and bloom formation by filamentous cyanobacteria
877	Planktothrix. Harmful Algae 54, 69-86.
878	
879	Kurmayer, R., Schober, E., Tonk, L., Visser, P.M. and Christiansen, G. (2011) Spatial
880	divergence in the proportions of genes encoding toxic peptide synthesis among
881	populations of the cyanobacterium Planktothrix in European lakes. FEMS Microbiol
882	Lett. 317(2), 127-137.
883	
884	Le Manach, S., Khenfech, N., Huet, H., Qiao, Q., Duval, C., Marie, A., Bolbach, G., Clodic
885	G., Djediat, C., Bernard, C., Edery, M. and Marie, B. (2016) Gender-Specific
886	Toxicological Effects of Chronic Exposure to Pure Microcystin-LR or Complex

887	Microcystis aeruginosa Extracts on Adult Medaka Fish. Environmental Science &
888	Technology 50(15), 8324-8334.
889	
890	Liang, Y., Ouyang, K., Chen, X.L., Su, Y.Q. and Yang, J.X. (2017) Life strategy and grazing
891	intensity responses of Brachionus calyciflorus fed on different concentrations of
892	microcystin-producing and microcystin-free Microcystis aeruginosa. Sci. Rep. 7.
893	
894	Lifshits, M. and Carmeli, S. (2012) Metabolites of Microcystis aeruginosa Bloom Material
895	from Lake Kinneret, Israel. J. Nat. Prod. 75(2), 209-219.
896	
897	Liu, W.Y., Wang, L.Q., Yang, X.H., Zeng, H., Zhang, R.P., Pu, C.W., Zheng, C.F., Tan, Y.,
898	Luo, Y., Feng, X.B., Tian, Y.Q., Xiao, G.S., Wang, J., Huang, Y.J., Luo, J.H., Feng,
899	L., Wang, F., Yuan, C.Y., Yao, Y.A., Qiu, Z.Q., Chen, J.A., Wu, L.P., Nong, Q.Q., Lin,
900	H. and Shu, W.Q. (2017) Environmental Microcystin Exposure Increases Liver Injury
901	Risk Induced by Hepatitis B Virus Combined with Aflatoxin: A Cross-Sectional Study in
902	Southwest China. Environmental Science & Technology 51(11), 6367-6378.
903	
904	Lopes, V.R., Ramos, V., Martins, A., Sousa, M., Welker, M., Antunes, A. and Vasconcelos,
905	V.M. (2012) Phylogenetic, chemical and morphological diversity of cyanobacteria from
906	Portuguese temperate estuaries. Mar. Environ. Res. 73, 7-16.
907	
908	Mackintosh, C., Beattie, K.A., Klumpp, S., Cohen, P. and Codd, G.A. (1990) Cyanobacterial
909	Microcystin-Lr Is a Potent and Specific Inhibitor of Protein Phosphatase-1 and
910	Phosphatase-2a from Both Mammals and Higher-Plants. FEBS Lett. 264(2), 187-192.
911	

912	Matsuda, F., Tomita, A. and Shimizu, H. (2017) Prediction of Hopeless Peptides Unlikely to
913	be Selected for Targeted Proteome Analysis. Mass Spectrometry 6(1).
914	
915	Mazur-Marzec, H., Kaczkowska, M.J., Blaszczyk, A., Akcaalan, R., Spoof, L. and Meriluoto,
916	J. (2013) Diversity of peptides produced by Nodularia spumigena from various
917	geographical regions. Mar. Drugs 11, 1-19.
918	
919	Mazur-Marzec, H., Torunska-Sitarz, A., Fidor, A., Bertos-Fortis, M. and Legrand, C. (2016)
920	Chemical and Genetic Diversity of Nodularia spumigena from the Baltic Sea. Marine
921	Drugs 14(11).
922	
923	Merel, S., Walker, D., Chicana, R., Snyder, S., Baures, E. and Thomas, O. (2013) State of
924	knowledge and concerns on cyanobacterial blooms and cyanotoxins. Environ. Int. 59,
925	303-327.
926	
927	Meriluoto, J., Spoof, L. and Codd, G.A. (2017) Handbook of Cyanobacterial Monitoring and
928	Cyanotoxin Analysis, Wiley.
929	
930	Miller, T.R., Beversdorf, L.J., Weirich, C.A. and Bartlett, S.L. (2017) Cyanobacterial Toxins
931	of the Laurentian Great Lakes, Their Toxicological Effects, and Numerical Limits in
932	Drinking Water. Marine Drugs 15(6).
933	
934	Muller, D., Krick, A., Kehraus, S., Mehner, C., Hart, M., Kupper, F.C., Saxena, K., Prinz, H.,
935	Schwalbe, H., Janning, P., Waldmann, H. and Konig, G.M. (2006) Brunsvicamides A-C:

936	Sponge-related cyanobacterial peptides with Mycobacterium tuberculosis protein
937	tyrosine phosphatase inhibitory activity. J. Med. Chem. 49(16), 4871-4878.
938	
939	Murakami, M., Ishida, K., Okino, T., Okita, Y., Matsuda, H. and Yamaguchi, K. (1995)
940	Aeruginosins 98-A and B, trypsin inhibitors from the blue-green alga Microcystis
941	aeruginosa (NIES-98). Tetrahedron Lett. 36(16), 2785-2788.
942	
943	Murakami, M., Suzuki, S., Itou, Y., Kodani, S. and Ishida, K. (2000) New anabaenopeptins,
944	potent carboxypeptidase-A inhibitors from the cyanobacterium Aphanizomenon flos-
945	aquae. Journal of Natural Products 63(9), 1280-1282.
946	
947	Namikoshi, M. and Rinehart, K.L. (1996) Bioactive compounds produced by cyanobacteria.
948	J. Ind. Microbiol. Biotechnol. 17(5/6), 373-384.
949	
950	Neilan, B.A., Pearson, L.A., Muenchhoff, J., Moffitt, M.C. and Dittmann, E. (2013)
951	Environmental conditions that influence toxin biosynthesis in cyanobacteria.
952	Environmental Microbiology 15(5), 1239-1253.
953	
954	O'Neil, J.M., Davis, T.W., Burford, M.A. and Gobler, C.J. (2012) The rise of harmful
955	cyanobacteria blooms: The potential roles of eutrophication and climate change. Harmful
956	Algae 14, 313-334.
957	
958	Okino, T., Matsuda, H., Murakami, M. and Yamaguchi, K. (1993) Microginin, an
959	angiotensin-converting enzyme inhibitor from the blue-green alga Microcystis
960	aeruginosa. Tetrahedron Lett. 34(3), 501-504.

961	
962	Ostermaier, V. and Kurmayer, R. (2010) Application of real-time PCR to estimate toxin
963	production by the cyanobacterium Planktothrix sp. Appl. Environ. Microbiol. 76(11),
964	3495-3502.
965	
966	Otten, T.G., Paerl, H.W., Dreher, T.W., Kimmerer, W.J. and Parker, A.E. (2017) The
967	molecular ecology of Microcystis sp. blooms in the San Francisco Estuary. Environ.
968	Microbiol. 19(9), 3619-3637.
969	
970	Pilotto, L.S., Douglas, R.M., Burch, M.D., Cameron, S., Beers, M., Rouch, G.J., Robinson,
971	P., Kirk, M., Cowie, C.T., Hardiman, S., Moore, C. and Attewell, R.G. (1997) Health
972	effects of exposure to cyanobacteria (blue-green algae) during recreational water-related
973	activities. Australian and New Zealand Journal of Public Health 21(6), 562-566.
974	
975	Portmann, C., Blom, J.F., Gademann, K. and Juttner, F. (2008a) Aerucyclamides A and B:
976	isolation and synthesis of toxic ribosomal heterocyclic peptides from the cyanobacterium
977	Microcystis aeruginosa PCC 7806. J. Nat. Prod. 71(7), 1193-1196.
978	
979	Portmann, C., Blom, J.F., Kaiser, M., Brun, R., Juttner, F. and Gademann, K. (2008b)
980	Isolation of aerucyclamides C and D and structure revision of microcyclamide 7806A:
981	Heterocyclic ribosomal peptides from Microcystis aeruginosa PCC 7806 and their
982	antiparasite evaluation. J. Nat. Prod. 71(11), 1891-1896.
983	

43

984	Pouria, S., de Andrade, A., Barbosa, J., Cavalcanti, R.L., Barreto, V.T.S., Ward, C.J., Preiser,
985	W., Poon, G.K., Neild, G.H. and Codd, G.A. (1998) Fatal microcystin intoxication in
986	haemodialysis unit in Caruaru, Brazil. Lancet 352(9121), 21-26.
987	
988	Rantala, A., Fewer, D.P., Hisbergues, M., Rouhiainen, L., Vaitomaa, J., Borner, T. and
989	Sivonen, K. (2004) Phylogenetic evidence for the early evolution of microcystin
990	synthesis. Proceedings of the National Academy of Sciences of the United States of
991	America 101(2), 568-573.
992	
993	Raveh, A. and Carmeli, S. (2009) Two novel biological active modified peptides from the
994	cyanobacterium Microcystis sp. Phytochem. Lett. 2(1), 10-14.
995	
996	Reshef, V. and Carmeli, S. (2001) Protease inhibitors from a water bloom of the
997	cyanobacterium Microcystis aeruginosa. Tetrahedron 57(14), 2885-2894.
998	
999	Rohrlack, T., Dittmann, E., Henning, M., Borner, T. and Kohl, J.G. (1999) Role of
1000	microcystins in poisoning and food ingestion inhibition of Daphnia galeata caused by the
1001	cyanobacterium Microcystis aeruginosa. Applied and Environmental Microbiology
1002	65(2), 737-739.
1003	
1004	Rohrlack, T., Skulberg, R. and Skulberg, O.M. (2009) Distribution of oligopeptide
1005	chemotypes of the cyanobacterium Planktothrix and their persistence in selected lakes in
1006	fennoscandia. J. Phycol. 45(6), 1259-1265.
1007	

1008	Rouhiainen, L., Vakkilainen, T., Siemer, B.L., Buikema, W., Haselkorn, R. and Sivonen, K.
1009	(2004) Genes coding for hepatotoxic heptapeptides (microcystins) in the cyanobacterium
1010	Anabaena strain 90. Applied and Environmental Microbiology 70(2), 686-692.
1011	
1012	Saker, M.L., Fastner, J., Dittmann, E., Christiansen, G. and Vasconcelos, V.M. (2005)
1013	Variation between strains of the cyanobacterium Microcystis aeruginosa isolated from a
1014	Portuguese river. J. Appl. Microbiol. 99(4), 749-757.
1015	
1016	Sano, T. and Kaya, K. (1995) Oscillamide-Y, a Chymotrypsin Inhibitor from Toxic
1017	Oscillatoria-Agardhii. Tetrahedron Letters 36(33), 5933-5936.
1018	
1019	Sanz, M., Andreote, A.P.D., Fiore, M.F., Dorr, F.A. and Pinto, E. (2015) Structural
1020	characterization of new peptide variants produced by cyanobacteria from the Brazilian
1021	atlantic coastal forest using liquid chromatography coupled to quadrupole time-of-flight
1022	tandem mass spectrometry. Mar. Drugs 13(6), 3892-3919.
1023	
1024	Scherer, M., Bezold, D. and Gademann, K. (2016) Investigating the toxicity of the
1025	aeruginosin chlorosulfopeptides by chemical synthesis. Angew. Chem., Int. Ed. 55(32),
1026	9427-9431.
1027	
1028	Scherer, M. and Gademann, K. (2017) Total synthesis and structural revision of Aeruginosin
1029	KT608A. Org. Lett. 19(14), 3915-3918.
1030	
1031	Schindler, D.W. (2006) Recent advances in the understanding and management of
1032	eutrophication. Limnol. Oceanogr. 51(1), 356-363.

1033	
1034	Schirmer, K., Fischer, B.B., Madureira, D.J. and Pillai, S. (2010) Transcriptomics in
1035	ecotoxicology. Anal. Bioanal. Chem. 397(3), 917-923.
1036	
1037	Schreuder, H., Liesum, A., Lonze, P., Stump, H., Hoffmann, H., Schiell, M., Kurz, M., Toti,
1038	L., Bauer, A., Kallus, C., Klemke-Jahn, C., Czech, J., Kramer, D., Enke, H.,
1039	Niedermeyer, T.H.J., Morrison, V., Kumar, V. and Bronstrup, M. (2016) Isolation, Co-
1040	Crystallization and Structure-Based Characterization of Anabaenopeptins as Highly
1041	Potent Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa). Sci.
1042	Rep. 6.
1043	
1044	Schwartz, R.E., Hirsch, C.F., Sesin, D.F., Flor, J.E., Chartrain, M., Fromtling, R.E., Harris,
1045	G.H., Salvatore, M.J., Liesch, J.M. and Yudin, K. (1990) Pharmaceuticals from Cultured
1046	Algae. Journal of Industrial Microbiology 5(2-3), 113-123.
1047	
1048	Schymanski, E.L., Jeon, J., Gulde, R., Fenner, K., Ruff, M., Singer, H.P. and Hollender, J.
1049	(2014) Identifying Small Molecules via High Resolution Mass Spectrometry:
1050	Communicating Confidence. Environmental Science & Technology 48(4), 2097-2098.
1051	
1052	Sedmak, B., Elersek, T., Grach-Pogrebinsky, O., Carmeli, S., Sever, N. and Lah, T.T. (2008)
1053	Ecotoxicologically relevant cyclic peptides from cyanobacterial bloom (Planktothrix
1054	rubescens) - a threat to human and environmental health. Radiology and Oncology 42(2),
1055	102-113.
1056	

1057	Sharma, V.K., Triantis, T.M., Antoniou, M.G., He, X.X., Pelaez, M., Han, C.S., Song, W.H.,
1058	O'Shea, K.E., de la Cruz, A.A., Kaloudis, T., Hiskia, A. and Dionysiou, D.D. (2012)
1059	Destruction of microcystins by conventional and advanced oxidation processes: A
1060	review. Sep. Purif. Technol. 91, 3-17.
1061	
1062	Shishido, T.K., Jokela, J., Fewer, D.P., Wahlsten, M., Fiore, M.F. and Sivonen, K. (2017)
1063	Simultaneous Production of Anabaenopeptins and Namalides by the Cyanobacterium
1064	Nostoc sp CENA543. ACS Chem. Biol. 12(11), 2746-2755.
1065	
1066	Smutna, M., Babica, P., Jarque, S., Hilscherova, K., Marsalek, B., Haeba, M. and Blaha, L.
1067	(2014) Acute, chronic and reproductive toxicity of complex cyanobacterial blooms in
1068	Daphnia magna and the role of microcystins. Toxicon 79, 11-18.
1069	
1070	Svircev, Z., Drobac, D., Tokodi, N., Mijovic, B., Codd, G.A. and Meriluoto, J. (2017)
1071	Toxicology of microcystins with reference to cases of human intoxications and
1072	epidemiological investigations of exposures to cyanobacteria and cyanotoxins. Arch.
1073	Toxicol. 91(2), 621-650.
1074	
1075	Swain, S.S., Paidesetty, S.K. and Padhy, R.N. (2017) Antibacterial, antifungal and
1076	antimycobacterial compounds from cyanobacteria. Biomedicine & Pharmacotherapy 90,
1077	760-776.
1078	
1079	Szymanski, P., Markowicz, M. and Mikiciuk-Olasik, E. (2012) Adaptation of High-
1080	Throughput Screening in Drug Discovery-Toxicological Screening Tests. International
1081	Journal of Molecular Sciences 13(1), 427-452.

1082	
1083	Teneva, I., Asparuhova, D., Dzhambazov, B., Mladenov, R. and Schirmer, K. (2003) The
1084	freshwater cyanobacterium Lyngbya aerugineo-coerulea produces compounds toxic to
1085	mice and to mammalian and fish cells. Environ. Toxicol. 18(1), 9-20.
1086	
1087	Teneva, I., Dzhambazov, B., Koleva, L., Mladenov, R. and Schirmer, K. (2005) Toxic
1088	potential of five freshwater Phormidium species (Cyanoprokaryota). Toxicon 45(6), 711-
1089	725.
1090	Trout-Haney, J.V., Wood, Z.T. and Cottingham, K.L. (2016) Presence of the Cyanotoxin
1091	Microcystin in Arctic Lakes of Southwestern Greenland. Toxins 8(9).
1092	
1093	van de Waterbeemd, H. and Gifford, E. (2003) ADMET in silico modelling: Towards
1094	prediction paradise? Nature Reviews Drug Discovery 2(3), 192-204.
1095	
1096	Van Wagoner, R.M., Drummond, A.K. and Wright, J.L.C. (2007) Biogenetic diversity of
1097	cyanobacterial metabolites. Advances in Applied Microbiology, Vol 61 61, 89-217.
1098	
1099	Von Elert, E., Oberer, L., Merkel, P., Huhn, T. and Blom, J.F. (2005) Cyanopeptolin 954, a
1100	Chlorine-Containing Chymotrypsin Inhibitor of Microcystis aeruginosa NIVA Cya 43. J.
1101	Nat. Prod. 68(9), 1324-1327.
1102	
1103	Walker, H.W. (2014) Harmful Algae Blooms in Drinking Water, Removal of Cyanobacterial
1104	Cells and Toxins, CRC Press.
1105	

1106	Walther, T., Renner, S., Waldmann, H. and Arndt, H.D. (2009) Synthesis and Structure				
1107	Activity Correlation of a Brunsvicamide-Inspired Cyclopeptide Collection.				
1108	Chembiochem 10(7), 1153-1162.				
1109					
1110	Wang, G.D. and Cole, R.B. (1994) Disparity between Solution-Phase Equilibria and Change				
1111	State Distributions in Positive-Ion Electrospray Mass-Spectrometry (Vol 29, Pg 419				
1112	1994). Organic Mass Spectrometry 29(11), Cp2-Cp2.				
1113					
1114	Welker, M., Brunke, M., Preussel, K., Lippert, I. and von Döhren, H. (2004) Diversity and				
1115	distribution of Microcystis (Cyanobacteria) oligopeptide chemotypes from natural				
1116	communities studied by single-colony mass spectrometry. Microbiology-Sgm 150, 1785-				
1117	1796.				
1118					
1119	Welker, M., Marsalek, B., Sejnohova, L. and von Döhren, H. (2006) Detection and				
1120	identification of oligopeptides in Microcystis (cyanobacteria) colonies: Toward an				
1121	understanding of metabolic diversity. Peptides (N. Y., NY, U. S.) 27(9), 2090-2103.				
1122					
1123	Welker, M. and von Döhren, H. (2006) Cyanobacterial peptides - Nature's own combinatoria				
1124	biosynthesis. Fems Microbiology Reviews 30(4), 530-563.				
1125					
1126	Whitton, B.A. (2012) Ecology of Cyanobacteria II: Thier Diversity in Space and Time				
1127	Springer/Dordrecht, Heidelberg/New York/London.				
1128					
1129	Yuan, M., Namikoshi, M., Otsuki, A., Watanabe, M.F. and Rinehart, K.L. (1999)				
1130	Electrospray ionization mass spectrometric analysis of microcystins, cyclic heptapeptid				

1131	hepatotoxins: Modulation of charge states and [M+H](+) to [M+Na](+) ratio. Journal of			
1132	the American Society for Mass Spectrometry 10(11), 1138-1151.			
1133				
1134	Zhang, K. and Zhao, Y. (2018) Reduced Zebrafish Transcriptome Atlas toward			
1135	Understanding Environmental Neurotoxicants. Environmental Science & Technology			
1136	52(12), 7120-7130.			
1137				
1138	Zikova, A., Trubiroha, A., Wiegand, C., Wuertz, S., Rennert, B., Pflugmacher, S., Kopp, R.,			
1139	Mares, J. and Kloas, W. (2010) Impact of microcystin containing diets on physiological			
1140	performance of Nile tilapia (Oreochromis niloticus) concerning stress and growth.			
1141	Environ. Toxicol. Chem. 29(3), 561-568.			
1142				

4	T T .	1 1 .	1 .
1	H16	Th li	ghts
_	1112	<u> </u>	21113

- Lack of studies on cyanopeptides beyond microcystins especially in environmental
- 3 sciences
- Occurrence of cyanopeptides comparable in frequency and concentration to
- 5 microcystins
- Cyanopeptides inhibit various proteases in the nanomolar range (IC50)
- Key challenge for risk assessment is the structural diversity of cyanopeptides
- Identify priority candidates of potentially abundant, persistent, and toxic
- 9 cyanopeptides

Who is abundant + persistent + toxic?

